Drug data last refreshed 12h ago · AI intelligence enriched 1w ago
EXOSURF NEONATAL is an intratracheal suspension approved in 1990 for neonatal respiratory distress syndrome, representing one of the earliest synthetic pulmonary surfactant therapies. The product is a small-molecule formulation designed to restore surfactant function in premature infants' lungs. It works by reducing surface tension in the alveoli, improving lung compliance and gas exchange.
With LOE approaching and moderate competitive pressure (30/100), this mature neonatal product likely operates with a lean, specialized team focused on market defense rather than expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on EXOSURF NEONATAL offers limited career expansion; the product is in LOE phase with no linked job openings, reflecting organizational right-sizing around a mature asset. Career mobility is constrained to incremental commercial roles with minimal innovation or launch-phase opportunities.
Worked on EXOSURF NEONATAL at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.